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Objectives: Criteria for the selection of patients for adjuvant chemotherapy in intrahepatic cholangio-
carcinoma (IHCC) are lacking. Some authors advocate treating patients with lymph node (LN) involve-
ment; however, nodal assessment is often inadequate or not performed. This study aimed to identify
surrogate criteria based on characteristics of the primary tumour.
Methods: A total of 58 patients who underwent resection for IHCC between January 2000 and January
2010 at any of three institutions were identified. Primary outcome was overall survival (OS).
Results: Median OS was 23.0 months. Median tumour size was 6.5 cm and the median number of
lesions was one. Overall, 16% of patients had positive margins, 38% had perineural invasion (PNI), 40%
had lymphovascular invasion (LVI) and 22% had LN involvement. A median of two LNs were removed and
a median of zero were positive. Lymph nodes were not sampled in 34% of patients. Lymphovascular
and perineural invasion were associated with reduced OS [9.6 months vs. 32.7 months (P = 0.020) and
10.7 months vs. 32.7 months (P = 0.008), respectively]. Lymph node involvement indicated a trend
towards reduced OS (10.7 months vs. 30.0 months; P = 0.063). The presence of either LVI or PNI in
node-negative patients was associated with a reduction in OS similar to that in node-positive patients
(12.1 months vs. 10.7 months; P = 0.541). After accounting for adverse tumour factors, only LVI and PNI
remained associated with decreased OS on multivariate analysis (hazard ratio 4.07, 95% confidence
interval 1.60–10.40; P = 0.003).
Conclusions: Lymphovascular and perineural invasion are separately associated with a reduction in OS
similar to that in patients with LN-positive disease. As nodal dissection is often not performed and the
number of nodes retrieved is frequently inadequate, these tumour-specific factors should be considered
as criteria for selection for adjuvant chemotherapy.
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Introduction
Cholangiocarcinoma (CC) is the most common primary hepatic
malignancy after hepatocellular carcinoma. It affects 5000–8000
individuals per year in the USA1 and globally accounts for 3%
of all gastrointestinal malignancies.2 Cholangiocarcinoma is an
aggressive cancer in which longterm survival is poor as a result
of the late presentation of disease and the limited therapies
available. Indeed, the overall mortality rate in CC approaches its
incidence.1
Cholangiocarcinoma is divided into three general categories
according to whether the anatomic location of origin of disease is
intrahepatic, hilar or distal. Although hilar CC remains the most
common type, the incidence of intrahepatic cholangiocarcinoma
(IHCC) is rising3–5 and IHCC currently accounts for 20% of all
CC.5 Many believe that the anatomic location of CC corresponds
to specific and distinct tumour biology, as evidenced by separate
staging systems for intrahepatic, hilar and distal tumours; there-
fore, each type of CC should be considered separately. This study
focuses specifically on IHCC.
Resection is the mainstay of treatment for IHCC and offers
the only opportunity for cure. Resectability rates in IHCC range
from 46% to 75%.6 Improved surgical technique and refinements
in patient selection and perioperative care have contributed
to increased survival in resectable IHCC.7 Unfortunately, even
after complete resection, 5-year survival in IHCC remains poor
(5–43%), indicating that resection alone is not sufficient for most
patients.1,8
Current chemotherapy regimens are only marginally effective
and gemcitabine monotherapy has not been shown to be benefi-
cial in the adjuvant setting.9 No guidelines for adjuvant therapy
for IHCC exist.10 Recently, the Advanced Biliary Cancer (ABC)
Trial demonstrated improved survival in patients with advanced-
stage disease who received doublet chemotherapy, consisting of
gemcitabine and cisplatin, compared with gemcitabine mono-
therapy (11.7 months vs. 8.1 months; P < 0.001).11 It is possible
that the survival advantage of this more aggressive doublet
regimen may translate to the adjuvant setting, but this must be
evaluated in a prospective clinical trial. The benefit of adjuvant
therapy in resected IHCC will undoubtedly depend on appropri-
ate patient selection.
The presence of lymph node (LN) metastases is commonly
utilized to select patients for adjuvant therapy after complete
resection of many gastrointestinal malignancies, including
IHCC.12–15 However, portal lymphadenectomy is not routinely
performed in IHCC and its use remains controversial.6,8,16–18 Fur-
thermore, when it is performed, its nodal yield is often inadequate
for accurate staging. Given the frequent lack of information
regarding nodal status in IHCC, the present study sought to iden-
tify a surrogate marker for adverse tumour biology based on the
characteristics of the primary tumour. The authors have previ-
ously shown lymphovascular invasion (LVI) to be an independent
prognostic factor for shortened overall survival (OS) in a single-
institution series of resected hilar and intrahepatic CC.19 The
current multi-institution study focuses specifically on prognostic
factors in resected IHCC.
Materials and methods
Hepatobiliary resection databases at three institutions (Emory
University, University of Wisconsin and Ohio State University)
were reviewed for all patients with a diagnosis of IHCC
who underwent resection between January 2000 and January
2010. Permission from the institutional review board of
each institution was obtained prior to data review. Health
Insurance Portability and Accountability Act compliance was
ensured.
A total of 58 patients who underwent resection for IHCC were
identified. Thirty-five of these patients had been included in a
prior analysis that assessed the value of LVI in a single-institution
series of intrahepatic and hilar CC.19 Data for these 35 patients
are now reanalysed with updated follow-up, along with data for a
different cohort of patients who underwent treatment for IHCC
at two other institutions. Overall survival was ascertained
through the clinical follow-up documented in each patient’s
medical record and the Social Security Death Index. Pathology
reports were reviewed for important tumour factors that are
known to have prognostic value for patient survival. These
include tumour size, number and grade, margin status, LN
involvement, and the presence of LVI or perineural invasion
(PNI).15,20,21 Patients who did not undergo LN dissection were
regarded as node-negative as this is consistent with clinical prac-
tice patterns. Perioperative mortality was defined as death within
90 days of operation.
Statistical analysis
Data were analysed using spss Version 17.0 for Windows (SPSS,
Inc., Chicago, IL, USA). Kaplan–Meier log-rank survival analysis
was used to determine the association of each pathologic factor
with patient survival. Univariate Cox regression analysis was per-
formed for adverse tumour factors to determine their association
with OS. Factors significant at a level of P < 0.2 were included in
a multivariate Cox regression model.
Results
A total of 58 patients underwent resection. The median age of the
study sample was 66 years (range: 29–89 years); 38 patients (66%)
were female. Pathologic and perioperative variables are summa-
rized in Table 1. Thirteen patients had pathologically proven LN
disease. Rates of LN positivity ranged from 22% in all patients in
this study to 34% in those who underwent LN procurement with
pathologic assessment (n = 38). Because of the referral patterns of
the three institutions, data on adjuvant therapy are limited. Of the
48 patients whose adjuvant treatment status is known, 13 patients
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received chemotherapy and six received radiation therapy. Precise
information on the chemotherapy regimen was not available.
Survival analysis
The median follow-up in survivors was 22.0 months (range: 0.4–
81.4 months). At the time of last follow-up, 35 patients (60%) had
died. Median OS in all patients was 23.0 months (range: 0.3–
81.4 months). The results of univariate and multivariate Cox
regression analyses for OS are shown in Table 2.
Lymph node involvement resulted in a strong trend towards
reduced OS (10.7 months vs. 30.0 months; P = 0.063) (Fig. 1a). A
subset analysis of patients who did not undergo lymphadenec-
tomy compared with those who were pathologically identified as
LN-negative did not demonstrate any difference in survival
(54.4 months vs. 21.1 months; P = 0.234) (Fig. 1b). Lymphovas-
cular invasion was associated with reduced OS (9.6 months vs.
32.7 months; P = 0.020) (Fig. 2a). Perineural invasion was also
associated with reduced OS (10.7 months vs. 32.7 months; P =
0.008) (Fig. 2b). A representative image demonstrating LVI and
PNI is shown in Fig. 3.
Lymphovascular and perineural invasion were statistically
more likely to occur within the same tumour specimen [LVI+/
PNI+: 24.1%; LVI+/PNI-: 15.5%; LVI-/PNI+: 13.8%; LVI-/PNI-:
46.6% (P = 0.008)], but the presence of both LVI and PNI did not
portend worse survival compared with the presence of either
alone (Fig. 4). There was no association between LN positivity and
the presence of LVI [LN+/LVI+: 12.1%; LN-/LVI+: 27.6% (P =
0.387)] or between LN positivity and the presence of PNI [LN+/
PNI+: 13.8%; LN-/PNI+: 24.1% (P = 0.095)]. In a subset analysis
of node-negative patients only (n = 45), LVI demonstrated a
strong trend towards reduced survival (12.1 months vs.
45.8 months; P = 0.124) (Fig. 5a). In the same subset of
LN-negative patients, PNI was significantly associated with
reduced OS (12.1 months vs. 32.7 months; P = 0.052) (Fig. 5b). In
node-negative patients, the presence of either LVI or PNI was
associated with reduced OS (12.1 months) similar to that in
patients with node-positive disease (10.7 months) (P = 0.541)
(Fig. 6). After accounting for adverse tumour factors including
tumour size and number, margin status, grade, and LN status,
only the presence of LVI or PNI persisted as negative prognostic
factors for reduced OS in a multivariate Cox regression analysis
(hazard ratio 4.07, 95% confidence interval 1.60–10.40; P = 0.003)
(Table 2).
Discussion
Cholangiocarcinoma is a deadly disease with an overall mortality
rate that is similar to its incidence.22 Resection offers the only
chance for cure, yet 5-year survival in this population remains
< 40% in most studies.23–25 Despite this dismal prognosis, evidence
supporting the use of adjuvant chemotherapy after complete
resection of IHCC is lacking.10,15,26 Recently, the ABC-02 Trial
demonstrated an improvement in OS in the advanced disease
setting with a doublet chemotherapy regimen of gemcitabine and
cisplatin.11 It remains to be determined whether or not this advan-
tage will transfer to the adjuvant setting. As with other malignan-
cies, appropriate selection of patients for adjuvant therapy will be
key to maximizing therapeutic benefits while minimizing toxicity.
The presence of adverse pathologic factors, such as LN
metastases, is commonly utilized to select patients for adjuvant
Table 1 Clinicopathologic characteristics of patients with intrahe-
patic cholangiocarcinoma (n = 58)
Variable Patients, n (%) Median (range)
Operative characteristics
Estimated blood loss, ml 500 (50–4000)
Type of resection
Left hepatectomy 14 (24%)
Left lateral sectorectomy 6 (10%)
Left trisegmentectomy 1 (2%)
Right hepatectomy 8 (14%)
Right trisegmentectomy 10 (17%)
Extended right
hepatectomy
13 (23%)
Other 6 (10%)
Pathologic characteristics
Positive margin 9 (16%)
Tumour size, cm 6.5 (1.3–21)
Tumour size 6.5 cm 32 (55%)
Number of lesions 1 (1–7)
Multiple tumours 12 (21%) 2 (2–7)
No lymphadenectomy
performed
20 (34%)
Lymph node-positive disease 13 (22%)
Number of nodes retrieved 2 (1–10)
Number of positive nodes 0 (0–5)
Differentiation
Good 3 (5%)
Moderate 32 (55%)
Poor 19 (33%)
Unknown 4 (7%)
Lymphovascular invasion 23 (40%)
Perineural invasion 22 (38%)
Postoperative course
Length of hospital stay, days 8 (1–44)
Complications 30 (52%)
Infectious 15 (26%)
Bleeding 3 (5%)
Bile leak 3 (5%)
Reoperation 3 (5%)
Perioperative 30-day mortality 6 (10%)
Perioperative 90-day mortality 8 (14%)
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therapy after complete resection of many gastrointestinal
malignancies.12–14 In IHCC, regional nodal involvement has been
shown to be a prognostic factor for reduced OS.6,17,18,27,28 The 7th
edition of the American Joint Committee on Cancer (AJCC)
staging system for IHCC takes into account LN involvement29 as it
correlates well with OS.17,30 In the present study, LN positivity
ranged from 22% in all patients to 34% in the subset of patients
who underwent LN procurement with pathologic assessment
(n = 38). This is consistent with a recent multi-institution series
that reported LN involvement in the range of 16–30%.17
In Western countries, however, portal lymphadenectomy is
not routinely performed for IHCC and its value remains
controversial.6,8,16–18 In the clinical setting, patients who do not
undergo lymphadenectomy are considered to be LN-negative in
decisions on adjuvant therapy. The current study is also subject to
this limitation, but it does represent an accurate reflection of
clinical practice, particularly as lymphadenectomy is not a stan-
dard of care in IHCC. A subset analysis of patients who did not
undergo lymphadenectomy compared with those who were
pathologically LN-negative did not demonstrate any difference in
survival. In fact, patients in whom LN status was unknown
displayed a trend towards improved survival (Fig. 1b). Thus, it
is unlikely that many of these patients harboured occult LN
metastases.
Furthermore, when portal LNs are removed, the median
number of nodes retrieved is generally fewer than three.17–19 This
Table 2 Factors associated with overall survival (90-day mortality excluded, n = 50)
Variable Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Positive margin 0.59 0.17–2.00 0.394 – – –
Tumour size 6.5 cm 1.11 0.49–2.54 0.805 – – –
Multiple tumours 1.73 0.77–3.90 0.188 0.91 0.35–2.35 0.839
Poor grade 2.23 0.92–5.42 0.077 2.52 0.94–6.77 0.066
Positive lymph node involvement 2.45 1.05–5.74 0.039 1.90 0.72–5.03 0.197
LVI or PNI 3.39 1.52–7.56 0.003 4.07 1.60–10.40 0.003
HR, hazard ratio; 95% CI, 95% confidence interval; LVI, lymphovascular invasion; PNI, perineural invasion.
1.0 Nx (n = 20)
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Figure 1 Nodal status and overall survival in (a) node-negative (Nx + N0) vs. node-positive patients, and (b) clinically node-negative (Nx) vs.
pathologically node-negative (N0) patients
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occurred in the present study, in which the median number of
nodes retrieved was only two. There are no specifications within
the AJCC guidelines as to the optimal number of nodes that must
be retrieved for accurate staging, but it is doubtful that such a
small number of nodes will enable a complete and accurate evalu-
ation. Ito et al. recently reported that the retrieval of six LNs was
necessary for accurate staging of extrahepatic CC.31 Given these
limitations of LN evaluation in IHCC, the aim of the present study
was to assess characteristics of the primary tumour that might
provide prognostic information similar to that indicated by LN
involvement to select patients for adjuvant therapy.
The present authors have previously demonstrated that the
presence of LVI is an independent prognostic factor for reduced
OS based on a single-institution series of resected CC, which
1.0 PNI-negative (n = 36)
PNI-positive (n = 22)
P = 0.008
32.7 months
10.7 months
0.8
0.6
0.4
0.2
0.0
0.0 10.0 20.0 30.0 40.0 50.0 60.0
1.0 LVI-negative (n = 35)
LVI-positive (n = 23)
P = 0.020
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(a) (b)
Figure 2 Overall survival in patients with and without (a) lymphovascular invasion (LVI) and (b) perineural invasion (PNI)
Figure 3 Histopathology shows (a) lymphovascular invasion as demonstrated by tumour cells (black arrow) within a vascular channel and (b)
perineural invasion with tumour cells (white arrow) within a neural bundle (*). (Haematoxylin and eosin stain; original magnification ¥400)
518 HPB
HPB 2012, 14, 514–522 © 2012 International Hepato-Pancreato-Biliary Association
included both hilar and intrahepatic disease sites.19 One of the
major limitations of that study was its inclusion of both hilar and
intrahepatic disease sites, which many regard as separate entities
with distinct tumour biology. The present study is a subsequent
investigation that focused only on IHCC. It included 35 patients
from the original study, analysed using updated follow-up data,
and a different cohort of patients treated at two other institutions.
In the current study, which is specific to IHCC, the presence of LVI
and/or PNI confers a negative prognostic effect on survival similar
to that implied by LN involvement. The authors propose that
these characteristics of the primary tumour may be a surrogate for
aggressive tumour behaviour and may serve as criteria for select-
ing for adjuvant therapy. Additionally, the presence of LVI and/or
PNI may be used to stratify patient populations in future studies
assessing the efficacy of adjuvant regimens.
The concept of LVI as an adverse prognostic marker is not
unique to CC. Tumoral lymphovascular involvement signifi-
cantly correlates with rates of LN metastases in breast cancer,32,33
endometrial cancer34,35 and colon cancer36 and is regarded as a
poor prognostic factor for survival.37,38 In the current series, the
presence of LVI did not correlate with the presence of nodal
disease. Although this may indicate inadequate LN sampling in
IHCC, as previously discussed, it does reflect clinical reality and
supports the suggestion that LVI is an independent negative
prognostic factor. Studies in node-negative breast cancer support
the concept of LVI as an independent poor prognostic factor for
OS.39
In a small single-institution study of only 22 patients with
pathologically node-negative IHCC, Shirabe and colleagues40
showed a high microvessel count (which is likely to represent a
surrogate for LVI) was an independent prognostic factor for poor
OS. In the current study, patients who did not undergo portal
lymphadenectomy were considered to have LN-negative disease as
this is a true representation of clinical practice patterns. Given the
rarity of IHCC and the heterogeneity in the performance of LN
dissections, a study to assess only histologically assessed LNs is
difficult outside the context of a prospective trial. A subset analysis
of clinically and pathologically node-negative patients (n = 45) in
the current study demonstrated a strong trend towards reduced
survival in patients with LVI (12.1 months vs. 45.8 months;
P = 0.124) (Fig. 5a). However, this subset analysis is somewhat
limited by the number of patients.
Like LVI, PNI has been implicated as a poor prognostic
factor in many cancer types, including squamous cell
carcinoma of the head and neck, cancer of the prostate, and
colorectal and pancreatic cancers.41–45 In a large series of hilar
and intrahepatic CC, Endo and colleagues showed that the
presence of PNI was significantly associated with reduced
OS.46 Several smaller single-institution series that included
only patients with IHCC have demonstrated a similar associa-
tion between PNI and shortened survival, but failed to show
the significance of PNI when accounting for other adverse
pathologic factors.8,47 In the authors’ recent single-institution
study, which included patients with both hilar and intrahepatic
CC, PNI marked a trend towards reduced OS, but this did not
reach statistical significance.19 In the current multi-institution
study on IHCC, the presence of PNI was found to be signifi-
cantly associated with a worse prognosis, even after accounting
for other known adverse factors, such as large tumour size, mul-
tiple tumours, positive resection margin, poor differentiation
and LN involvement. Although multiple tumours might be
expected to represent poor tumour biology and thus indicate
poor survival, most patients included in this series had solitary
tumours. Of the 12 patients with multiple lesions, more than
half (n = 7) had only two tumours. This fact, along with the
inherent difficulty of capturing the process of careful patient
selection for operation in a retrospective study, is likely to
explain the lack of prognostic significance of multiple tumours
in this series.
In the current study, lymphovascular and perineural invasion
demonstrated a parallel relationship in that, in a given patient,
positivity or negativity for one was likely to be reflected by,
respectively, positivity or negativity for the other. Studies of lym-
phatic and blood vessel invasion and PNI in gastric cancer
patients have shown similar findings.48–50 The presence of both
factors, however, did not portend a prognosis worse than that
implied by the presence of either alone (9.2 months vs.
11.9 months; P = 0.842) (Fig. 4). Thus, LVI and PNI both sepa-
rately and in combination confer equal but independent negative
prognostic effects on survival.
1.0 LVI- and PNI-negative (n = 27)
LVI or PNI (n = 17)
LVI and PNI (n = 14)
11.9 months
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Figure 4 Overall survival in patients with and without lymphovascu-
lar invasion (LVI) and perineural invasion (PNI) shows that the effects
of LVI and PNI are not additive
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Both LVI and PNI are routinely assessed in standard pathologic
evaluations of resected IHCC. As characteristics of the primary
tumour, LVI and PNI are not subject to the variability of LN
retrieval. The presence of either LVI or PNI is associated with
shortened OS equivalent to that in LN-positive disease. Given the
prospect of improved and more efficacious chemotherapy with
gemcitabine and cisplatin, the presence of LVI or PNI may repre-
sent a reproducible and reliable criterion for selecting patients for
adjuvant therapy after resection of IHCC.
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